Cargando…

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors

BACKGROUND: Treatment recommendations for patients with neuroendocrine tumors (NETs) include the use of octreotide long-acting release (LAR) for long-term therapy and immediate-release (IR) as rescue therapy to control the breakthrough symptoms of carcinoid syndrome (CS). High doses of LAR are commo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Yue, Anthony, Lowell, Delcher, Chris, Moga, Daniela C, Chauhan, Aman, Huang, Bin, Adams, Val
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243760/ https://www.ncbi.nlm.nih.gov/pubmed/36994847 http://dx.doi.org/10.1093/oncolo/oyad057

Ejemplares similares

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines
por: Exner, Samantha, et al.
Publicado: (2018)

Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study
por: von Arx, Claudia, et al.
Publicado: (2020)

Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors
por: Al-Efraij, Khalid, et al.
Publicado: (2015)

Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study
por: Li, Jie, et al.
Publicado: (2016)

Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands
por: Hagendijk, Marije E., et al.
Publicado: (2021)

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
por: Wang, Yuhong, et al.
Publicado: (2017)

Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients
por: Delle Cese, Francesca, et al.
Publicado: (2021)

Ontogenesis of Gonadotropin-Releasing Hormone Neurons: A Model for Hypothalamic Neuroendocrine Cell Development
por: Stevenson, Erica L., et al.
Publicado: (2013)

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
por: Yau, Hanford, et al.
Publicado: (2017)

Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review
por: Deng, Chao, et al.
Publicado: (2017)

Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study
por: Zhao, Zhe, et al.
Publicado: (2022)

Management of Large Cell Neuroendocrine Carcinoma
por: Corbett, Virginia, et al.
Publicado: (2021)

Immediate release fentanyl in general practices: Mostly off-label prescribing
por: Weesie, Yvette M., et al.
Publicado: (2023)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves
por: Akram, Ayesha
Publicado: (2021)

Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment
por: Nomoto, Hiroshi, et al.
Publicado: (2019)

Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
por: Marques-Pamies, Montserrat, et al.
Publicado: (2023)

Corticotropin-releasing factor-like diuretic hormone acts as a gonad-inhibiting hormone in adult female, Rhodnius prolixus
por: Al-Dailami, Areej N., et al.
Publicado: (2023)

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study
por: Verset, G, et al.
Publicado: (2007)

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis
por: Strosberg, Jonathan R, et al.
Publicado: (2015)

(177)Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience
por: Satapathy, Swayamjeet, et al.
Publicado: (2021)

Growth Hormone-Releasing Hormone in Diabetes
por: Fridlyand, Leonid E., et al.
Publicado: (2016)

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)
por: Adelman, Daphne, et al.
Publicado: (2020)

Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen
por: Devarakonda, Krishna, et al.
Publicado: (2015)

A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis
por: van Stein, Christina, et al.
Publicado: (2021)

Analysis of the Number of Euploid Embryos in Preimplantation Genetic Testing Cycles With Early-Follicular Phase Long-Acting Gonadotropin-Releasing Hormone Agonist Long Protocol
por: Li, Gang, et al.
Publicado: (2020)

Regulation of gonadotropins by corticotropin-releasing factor and urocortin
por: Kageyama, Kazunori
Publicado: (2013)

Epigenetic Control of Gonadotropin Releasing Hormone Neurons
por: Kurian, Joseph R., et al.
Publicado: (2013)

Central corticotropin releasing factor and social stress
por: Backström, Tobias, et al.
Publicado: (2013)

Clinical evaluation of switching from immediate‐release to prolonged‐release lithium in bipolar patients, poorly tolerant to lithium immediate‐release treatment: A randomized clinical trial
por: Pelacchi, Federica, et al.
Publicado: (2022)

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
por: Chauhan, Aman, et al.
Publicado: (2018)

Insights into the Control of Drug Release from Complex Immediate Release Formulations
por: Dong, Runqiao, et al.
Publicado: (2021)

Diabetes Insipidus Induced by Combination of Short-acting Octreotide and Lanreotide for Recurrent Carcinoid Crisis of Neuroendocrine Tumour: A Case Report
por: Guan, Goh Kian, et al.
Publicado: (2021)

Editorial: Gonadotropin-Releasing Hormone Receptor Signaling and Functions
por: Bjelobaba, Ivana, et al.
Publicado: (2018)

Gynecologic large cell neuroendocrine carcinoma: A review
por: Burkeen, Grant, et al.
Publicado: (2020)

Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature
por: Chauhan, Aman, et al.
Publicado: (2017)

Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment
por: LIU, YAO, et al.
Publicado: (2013)

Endocrine and paracrine characteristics of neuroendocrine prostate cancer
por: Arman, Tarana, et al.
Publicado: (2022)

Population Pharmacokinetic Modelling of the Complex Release Kinetics of Octreotide LAR: Defining Sub-Populations by Cluster Analysis
por: Kapralos, Iasonas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hifqrlei92sdanvi9brkfmi87j